Newer strategies for the treatment of heparin-induced thrombocytopenia

Pharmacotherapy

Volumn 19, Issue 2, 1999, Pages 181-195

  Warkentin, Theodore E ^a   Barkin, Robert L ^b,c  

^a MCMASTER UNIVERSITY   (Canada)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANCROD; ARGATROBAN; DANAPAROID; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG COST; DRUG INDICATION; DRUG INDUCED DISEASE; EMBOLECTOMY; GANGRENE; HUMAN; PATHOGENESIS; PHARMACODYNAMICS; PHARMACOKINETICS; PLASMAPHERESIS; REVIEW; THROMBECTOMY; THROMBOCYTOPENIA; THROMBOEMBOLISM;

HEPARIN; HUMANS; RANDOMIZED CONTROLLED TRIALS; THROMBOCYTOPENIA;

EID: 0032940776     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.3.181.30928     Document Type: Review

References (84)

1. Davidson B. 1995 American College of Chest Physicians (ACCP) consensus guidelines on antithrombotic therapy. Semin Thromb Haemost 1996;22(suppl 2):1-5.
2. Clagett GP. Prevention of postoperative venous thromboembolism: an update. Am J Surg 1994;168:515-22.
3. Greinacher A. Antigen generation in heparin-associated thrombocytopenia: the nonimmunologic type and the immunologic type are closely linked in their pathogenesis. Semin Thromb Haemost 1995;21:106-16.
4. Warkentin TE, Kelton JG. Interaction of heparin with platelets, including heparin-induced thrombocytopenia. In: Bounameaux H, ed. Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic diseases, vol 19. Fundamental and clinical cardiology. New York: Marcel Dekker, 1994:75-127.
5. Chong BH. Heparin-induced thrombocytopenia. Br J Haematol 1995;89:431-9.
6. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998;79:1-7.
7. Warkentin, TE Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-5.
8. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-7.
9. Arthur CK, Grant SJB, Murray WK, Isbister JP, Stiel JN, Lauer CS. Heparin-associated acute adrenal insufficiency. Aust NZ J Med 1985;15:454-5.
10. Ernest D, Fisher MM. Heparin-induced thrombocytopenia complicated by bilateral adrenal haemorrhage. Intensive Care Med 1991;17:238-40.
11. Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene complicating heparin-induced thrombocytopenia. Ann Intern Med 1997;127:804-12.
12. Kelton JG. Heparin-induced thrombocytopenia. Haemostasis 1986;16:173-86.
13. Greinacher A, Alban S. Heparinoids as an alternative for parenteral anticoagulation therapy in patients with heparin-induced thrombocytopenia. Hāmostaseologie 1996;16:41-9.
14. Warkentin TE, Kelton JG. Thrombocytopenia due to platelet destruction and hypersplenism. In: Hoffman R, Benz ER Jr, Shatti SJ, et al, eds. Hematology. Basic principles and practice, 3rd ed. New York: Churchill Livingston, in press.
15. Denomme GA, Warkentin TE, Horsewood P, Sheppard J-A, Warner MN, Kelton JG. Activation of platelets by sera containing IgG1 heparin-dependent antibodies: an explanation for the predominance of the FcγRIIa "low responder" (Hisl31) gene in patients with heparin-induced thrombocytopenia. J Lab Clin Med 1997;130:278-84.
16. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia [letter]. Thromb Haemost 1992;68:95-6.
17. Kelton JG, Smith JW, Warkentin TE, Hayward CPM, Denomme GA, Horsewood P. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994;83:3232-9.
18. Greinacher A, Pōtzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multi-molecular PF4-heparin complex as the major antigen. Thromb Haemost 1994;71:247-51.
19. Visentin GP, Ford S, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994;93:81-8.
20. Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: laboratory studies. Blood 1988;72:925-30.
21. Warkentin TE, Hayward CPM, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994;84:3691-9.
22. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987;316:581-9.
23. Greinacher A, Amiral J, Dummel V, Vissac A, Kiefel V, Mueller-Eckhardt C. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994;34:381-5.
24. Amiral J, Wolf M, Fischer AM, Boyer-Neumann C, Vissac AM, Meyer D. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996;92:954-9.
25. Amiral J, Marfaing-Koka A, Wolf M, et al. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 1996;88:410-16.
26. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986;67:27-30.
27. Warkentin TE, Hayward CPM, Smith CA, Kelly PM, Kelton JG. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 1992;120:371-9.
28. Greinacher A, Michels I, Kiefer V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 1991;66:734-6.
29. Kleinschmidt S, Seyfert UT. Heparin-associated thrombocytopenia (HAT) - still a diagnostic and therapeutical problem in clinical practice. Angiology 1995;46:37-44.
30. Favaloro EJ, Bernal-Hoyos E, Exner R, Koutts J. Heparin-induced thrombocytopenia: laboratory investigation and confirmation of diagnosis. Pathology 1992;24:177-83.
31. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993;69:344-50.
32. 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1995;104:648-54.
33. Amiral J, Bridey F, Wolf M, et al. Antibodies to macro-molecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost 1995;73:21-8.
34. Warkentin TE. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev 1996;10:249-58.
35. Reid HA, Chan KE, Thean PC. Prolonged coagulation defect (defibrination syndrome) in Malayan viper bite. Lancet 1963;1:621-6.
36. Wright JG, Geroulakos G. Ancrod: clinical indications and methods of use. Semin Vasc Surg 1996;9(4):315-28.
37. Demers C, Ginsberg JS, Brill-Edwards P, et al. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood 1991;78:2194-7.
38. Warkentin TE. Danaparoid (Orgaran) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: effects on in vivo thrombin and cross-linked fibrin generation, and evaluation of the clinical significance of in vitro cross-reactivity (XR) of danaparoid for HIT-IgG [abstr]. Blood 1996;88(suppl 1):626a.
39. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79(1):1-17.
40. Gordon DL, Linhardt R, Adams HP. Low-molecular-weight heparins and heparinoids and their use in acute or progressing ischemic stroke. Clin Neuropharmacol 1990;13(6):522-43.
41. Patrassi GM, Luzzatto G. Heparin-induced thrombocytopenia with thrombosis of the aorta, iliac arteries and right axillary vein successfully treated by low-molecular-weight heparin [letter]. Acta Haematol 1994;91:55-6.
42. Ramakrishna R, Manoharan A, Kwan YL, Kyle PW. Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran). Br J Haematol 1995;91:736-8.
43. Slocum MM, Adams JG Jr, Teel R, Spadone DP, Silver D. Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome. J Vasc Surg 1996;23:839-43.
44. Greinacher A, Michels I, Mueller-Eckardt C. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb Haemost 1992;67(5):545-9.
45. Visentin GP, Moghaddam M, Aster RH. Antibodies associated with heparin-induced thrombocytopenia/thrombosis (HITP) recognize sites on platelet factor 4 (PF4) induced by the binding of linear polyanionic compounds [abstr]. Thromb Haemost 1997;77(suppl):362.
46. Sobel M, Adelman B, Szentpetery S, Hoffman M, Posner MP, Jenvey W. Surgical management of heparin-associated thrombocytopenia. Strategies in the treatment of venous and arterial thromboembolism. J Vasc Surg 1988;8:395-401.
47. Mehta DP, Yoder EL, Appel J, Bergsman KL. Heparin-induced thrombocytopenia and thrombosis: reversal with streptokinase. A case report and review of literature. Am J Hematol 1991;36:275-9.
48. Nand S, Robinson JA. Plasmapheresis in the management of heparin-associated thrombocytopenia with thrombosis. Am J Hematol 1988;28:204-6.
49. Markwardt F. Hirudin: the promising antithrombotic. Cardiovasc Drug Rev 1992;10:211-32.
50. Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs 1995;49:856-84.
51. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clotbound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
52. Greinacher A, Volpel H, Potzsch B. Recombinant hirudin in the treatment of patients with heparin-induced thrombocytopenia (HIT) [abstr]. Blood 1996;88(suppl 1):281a.
53. Eichler P, Greinacher A. Anti-hirudin antibodies induced by recombinant hirudin in the treatment of patients with heparin-induced thrombocytopenia (HIT) [abstr]. Ann Hematol 1996;72(suppl):A4.
54. Matsuo R, Kario K, Chikahira Y, Nakao K, Yamada R. Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Br J Haematol 1992;82:627-9.
55. Danhof M, de Boer A, Magnani HN, Stiekema JCJ. Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis 1992;22:73-84.
56. Meuleman DG. Orgaran (Org 10172): its pharmacological profile in experimental models. Haemostasis 1992;22:58-65.
57. Magnani HN, Beijering JR, ten Cate JW, Chong BH. Orgaran anticoagulation for cardiopulmonary bypass surgery in patients with heparin-induced thrombocytopenia. In: Pifarre R, ed. New anticoagulants for the cardiovascular patient. Philadelphia: Hanley & Belfus, 1997:487-5.
58. Boneu B, Buchanan MR, Cade JF, et al. Effects of heparin, its low molecular weight fractions, and other glycosaminoglycans on thrombus growth in vivo. Thromb Res 1985;40:81-9.
59. Mikhailidis DP, Barradas MA, Mikhailidis AM, Magnani H, Dandona P. Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function. Br J Clin Pharmacol 1984;17:43-8.
60. Hobbelen PMJ, Vogel GMT, Meuleman DG. Time courses of antithrombotic effects, bleeding enhancing effects, and interactions with factors Xa of thrombin after administration of low molecular weight heparinoid Org 10172 or heparin to rats. Thromb Res 1987;48:549-58.
61. Skoutakis VA. Danaparoid in the prevention of thromboembolic complications. Ann Pharmacother 1997;31:876-87.
62. Comp PC, Voegeli T, McCutchen JW, et al. A comparison of danaparoid, a subcutaneous non-heparin containing anti-thrombotic agent, with warfarin for prophylaxis against deep vein thrombosis after hip joint replacement surgery. Orthopedics In press.
63. Gerhart TN, Yett HS, Robertson LK, Lee MA, Smith M, Salzman EW. Low-molecular-weight heparinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture of the hip. A prospective, randomized trial. J Bone Joint Surg 1991;73-A:494-502.
64. Bergqvist D, Kettunen K, Fredin H, et al. Thromboprophylaxis in patients with hip fractures: a prospective, randomized, comparative study between Org 10172 and dextran 70. Surgery 1991;109:617-22.
65. Leyvraz P, Bachmann F, Bohnet J, et al. Thromboembolic prophylaxis in total hip replacement: a comparison between the low molecular weight heparinoid Lomoparan and heparin-dihydroergotamine. Br J Surg 1992;79:911-14.
66. Gent M, Hirsh J, Ginsberg JS, et al. Low molecular weight heparinoid Orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Circulation 1996;93:80-4.
67. Hoek JA, Nurmohamed MT, Hamelynck KJ, et al. Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid. Thromb Haemost 1992;67:28-32.
68. Gallus A, Cade J, Ockleford P, et al. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicentre comparison. Thromb Haemost 1993;70:562-7.
69. Turpie AGG, Hirsh J, Jay RM, et al. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987;1:523-6.
70. de Valk HW, Banga JD, Wester JWJ, et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Intern Med 1995;123:1-9.
71. Henny CP, ten Cate H, Surachno S, et al. The effectiveness of a low molecular weight heparinoid in chronic intermittent haemodialysis. Thromb Haemost 1985;54:460-2.
72. Ireland H, Lane DA, Flynn A, Anastassiades E, Curtis JR. The anticoagulant effect of heparinoid Org 10172 during haemodialysis: an objective assessment. Thromb Haemost 1986;55:271-5.
73. Henny CP, ten Cate JW, van Bronswijk H, et al. Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications. Lancet 1983;1:890-3.
74. Organon, Inc. Orgaran (danaparoid sodium) package insert. West Orange, NJ;1997.
75. Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993;70:554-61.
76. Vun CM, Evans S, Chong BH. Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia. Thromb Res 1996;81:525-32.
77. Chong BH, Ismail F, Cade J, Gallus AS, Gordon S, Chesterman CN. Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood 1989;73:1592-6.
78. Makhoul RG, Greenberg CS, McCann RL. Heparin-associated thrombocytopenia and thrombosis: a serious clinical problem and potential solution J Vasc Surg 1986;4:522-8.
79. Chong BH, Magnani HN. Orgaran in heparin-induced thrombocytopenia. Haemostasis 1992;22:85-91.
80. Miller L, Niecestro R, Magnani H. Successful cardiopulmonary bypass surgery with Orgaran in patients with heparin-induced thrombocytopenia [abstr]. Thromb Haemost 1997;77(suppl): 446-7.
81. Greinacher A, Philippen KH, Kemkes-Matthes B, Mockl M, Mueller-Eckhardt C, Schaefer K. Heparin-associated thrombocytopenia type II in a patient with end-stage renal disease: successful anticoagulation with the low-molecular- weight heparinoid Org 10172 during haemodialysis. Nephrol Dial Transplant 1993;8:1176-7.
82. Brister SJ, Ofosu FA, Heigenhauser GJF, Gianese F, Buchanan MR. Is heparin the ideal anticoagulant for cardiopulmonary bypass? Dermatan sulphate may be an alternate choice. Thromb Haemost 1994;71:468-73.
83. Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia: know what to do. Medicine (N Am) 1995;18:942-9.
84. Abramovicz M, ed. Lepirudin for heparin-induced thrombocytopenia. Med Lett Drugs Ther 1998;40:94-5.